Device Trial Radar · NCT05947708
The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300
Last checked: Nov 20, 2026Latest source record: Jul 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Sep 15, 2019
Primary completion
Oct 15, 2019
Study completion Jan 15, 2020
Sponsor
- Lead sponsor
- Outset MedicalNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- White Plains Hospital
- First posted
- Jul 17, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study Goal is to determine the impact of dialysate flow rate (Qd) on Subject reported dialysis related symptoms and on time to recovery post dialysis.
Conditions
- End Stage Renal Disease on Dialysis
Interventions
Dialysate Flow RateDevice
Hemodialysis is completed with dialysate being used at differing flow rates. Flow rates will be modified to see if this is a causal factor in post-dialysis recovery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adequacy of Chronic DialysisTime frame: 4 weeks
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Outset Medical
San Jose, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.